Infiuss Health

Infiuss Health, a healthcare technology company on a mission to accelerate medical research.

[Infiuss Health @infiuss]

Cell therapy manufacturing is still one of the most fragile steps in getting a treatment to a patient. A vein-to-vein time of weeks sounds clinical, but for someone in relapse, every day of that window is a clinical variable. Scaling autologous therapies means rethinking logistic

[Infiuss Health @infiuss]

Synthetic control arms are gaining traction in rare disease trials, using historical patient data to stand in for a placebo group. It is a genuine lifeline when enrolling enough patients is nearly impossible. But the quality of that historical data determines everything. #RareDis

[Infiuss Health @infiuss]

Wearable biosensors can now capture endpoints that a clinic visit never could, continuous glucose, sleep architecture, cardiac rhythm over weeks. Regulatory agencies are still figuring out how to weight that data. The science is ahead of the framework, and that gap is real. #Regu

[Infiuss Health @infiuss]

Adaptive trial designs let sponsors modify dose, population, or endpoints mid-study based on interim data. Yet most sites still run them with the same operational playbook as fixed trials. The design is only as smart as the execution behind it. #TrialDesign

[Infiuss Health @infiuss]

Gene therapy pricing conversations always start too late. By the time a one-time curative therapy reaches a payer's desk, the reimbursement framework isn't built for it. Outcome-based contracts sound elegant, but they require data infrastructure most health systems don't have yet

[Infiuss Health @infiuss]

Most AI tools in radiology get validated on clean, curated datasets. Real hospital imaging archives are messier. Deployment performance rarely matches trial performance, and that gap deserves far more attention before we scale. #AIinHealthcare

[Infiuss Health @infiuss]

Companion diagnostics are quietly becoming the make-or-break factor in oncology approvals. A therapy's label can live or die on whether the right biomarker test reaches clinicians at the same time the drug does. Co-development is strategy, not paperwork. #Biotech

[Infiuss Health @infiuss]

FDA's embrace of real-world evidence in regulatory submissions is reshaping how we think about post-market studies. Waiting for a perfect randomized trial isn't always the right call when patients need answers now. #DigitalHealth

[Infiuss Health @infiuss]

Decentralized clinical trials sound like a win for patients. But when sites lose touch with participants, protocol deviations quietly pile up. Flexibility in trial design has to be matched with smarter remote monitoring, not just good intentions. #ClinicalTrials

[Infiuss Health @infiuss]

Pediatric drug development still leans heavily on extrapolating adult PK data. Kids aren't small adults, and organ maturation changes how a compound behaves in ways that dose-scaling alone doesn't capture. Age-appropriate formulation is a science problem, not just a packaging one

[Infiuss Health @infiuss]

Synthetic control arms are gaining traction in rare disease trials where randomization is near impossible. But the quality of the external data used to build that control is doing enormous scientific work, often with very little scrutiny. Garbage in, approval out. #RareDisease

[Infiuss Health @infiuss]

Most digital health apps reach FDA clearance through 510(k) predicate matching, not clinical validation. That means a tool can be legally marketed before anyone has tested whether it actually changes a patient outcome. Cleared and proven are not the same thing. #DigitalHealth

[Infiuss Health @infiuss]

FDA's accelerated approval pathway was designed for serious conditions with unmet need. What's underappreciated is how the confirmatory trial requirement, often negotiated post-approval, has become the real test of whether a drug earns its place on the market. #DrugRegulation

[Infiuss Health @infiuss]

mRNA platforms got their spotlight from vaccines, but the more quietly interesting application is personalized cancer neoantigen therapy. Every patient gets a different drug. That breaks almost every assumption traditional manufacturing and QC were built on. #Biotech

[Infiuss Health @infiuss]

Regulatory agencies are asking for real-world evidence earlier in the review cycle, but sponsors are still treating it as a post-approval obligation. That gap isn't just a submission strategy problem. It's reshaping which products reach patients and how fast. #HealthPolicy

[Infiuss Health @infiuss]

Cell therapy manufacturing is still a craft operation dressed up as a scalable process. Vein-to-vein time, yield variability, and cold chain failures aren't edge cases. They're the reason promising autologous therapies don't reach most patients who qualify. #CellTherapy

[Infiuss Health @infiuss]

Adaptive trial designs have been approved in principle for years, but most sponsors still default to fixed protocols. Not because adaptive is harder to run, it's harder to explain to a board that doesn't trust a moving target. Organizational risk appetite is shaping trial science

[Infiuss Health @infiuss]

Decentralized trials moved visits to patients' homes but kept the same visit-based data model underneath. If you're rethinking where care happens, you probably need to rethink what you're measuring and when. The logistics changed; the science hasn't caught up. #ClinicalResearch

[Infiuss Health @infiuss]

Gene therapy pricing models are built around a one-time cure narrative. But if durability data only goes out 5 years and the indication is pediatric, you're asking payers to bet on a lifetime benefit nobody has actually measured yet. That's a reimbursement design problem. #GeneTh

[Infiuss Health @infiuss]

Most AI tools in radiology get validated on clean, curated imaging datasets. Real hospital PACS archives are messier, with inconsistent acquisition protocols across machines and years. A model that aces a benchmark can quietly degrade in the clinic without anyone noticing. #MedAI